Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy

(2018) Elizabeth Louise Siegler et al.   HUMAN GENE THERAPY

Natural killer cell cytotoxicity and its regulation by inhibitory receptors

(2018) Santosh Kumar   IMMUNOLOGY

Role of natural killer cells in lung cancer

(2018) Ozge Nur Aktaş et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors

(2018) Vishal Jindal et al.   MEDICAL ONCOLOGY

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside

(2016) Qi Zhang et al.   OncoImmunology

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Natural killer cell immunotherapy to target stem-like tumor cells

(2016) Steven K. Grossenbacher et al.   Journal for ImmunoTherapy of Cancer

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

(2015) Rachel A. Burga et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

(2015) Garnet Suck et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural Killer Cell Adoptive Transfer Therapy

(2015) Zachary B. Davis et al.   CANCER JOURNAL

NK-92 cells engineered with anti-CD33 chimeric antigen receptors (CAR) for the treatment of Acute Myeloid Leukemia (AML)

(2015) Sarwish Rafiq et al.   CYTOTHERAPY

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

(2015) Kurt Schönfeld et al.   MOLECULAR THERAPY

Advantages and applications of CAR-expressing natural killer cells

(2015) Wolfgang Glienke et al.   Frontiers in Pharmacology

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

(2015) U. Koehl et al.   OncoImmunology

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

(2015) Jianfeng Han et al.   Scientific Reports

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation

(2014) N. N. Shah et al.   BLOOD

Enhanced Cytotoxicity of Natural Killer Cells following the Acquisition of Chimeric Antigen Receptors through Trogocytosis

(2014) Fu-Nan Cho et al.   PLoS One

Are natural killer cells superior CAR drivers?

(2014) Hans Klingemann   OncoImmunology

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer

(2013) Ebrahim Eftekhar et al.   MOLECULAR BIOLOGY REPORTS

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo

(2013) Zhenya Ni et al.   STEM CELLS

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

(2013) Laurent Boissel et al.   OncoImmunology

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

(2012) Christiane Sahm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model

(2012) B. E. Swift et al.   HAEMATOLOGICA

Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process

(2011) Jan Spanholtz et al.   PLoS One

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

(2009) T. Sutlu et al.   JOURNAL OF INTERNAL MEDICINE

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY